PARP Inhibitor based DNA Damage Response targeting Therapeutic Development Service
Introduction What We Can Offer Workflow Why Creative Biolabs Customer Reviews FAQs Related Services Contact Us
Creative Biolabs provides comprehensive support from initial target identification to preclinical proof-of-concept, ensuring your project advances efficiently and effectively. Clients can expect specific deliverables such as validated drug targets, optimized lead compounds with favorable pharmacokinetic profiles, robust preclinical efficacy data, and identified predictive biomarkers. Our problem-solving capabilities are rooted in decades of expertise in DNA repair biology and a deep understanding of cancer vulnerabilities, enabling us to design and execute studies that yield actionable insights.
Introduction of PARP Inhibitor-based DNA Damage Response-targeting Therapeutic Development Service
Creative Biolabs' PARP inhibitor-based DNA damage response-targeting therapeutic development service leads precision oncology. Leveraging DNA repair pathway vulnerabilities, especially in homologous recombination-deficient tumors sensitive to PARP inhibition, our approach is grounded in published synthetic lethality principles that revolutionized BRCA-mutated cancer treatments. We extend this foundation to explore "BRCAness" phenotypes and novel combination strategies, offering comprehensive solutions for next-generation targeted therapies.
Discover how we can help - Request a consultation.
Fig.1 Current model for PARP role in DNA damage repair and PARP inhibition – BRCA mutation synthetic lethality.1
What We Can Offer
At Creative Biolabs, our PARP inhibitor-based DDR-targeting therapeutic development service provides a comprehensive, customizable solution for your oncology programs.
Integrated Solutions
Our seamless, end-to-end service covers all PARP inhibitor development stages, from target validation to preclinical assessment. This integrated approach ensures consistent data flow and accelerates project progression by eliminating complexities often encountered when working with multiple vendors.
Diverse Model Capabilities
We utilize an extensive range of biological models, including patient-derived xenografts (PDXs) for highly translational in vivo studies, patient-derived organoids (PDOs) for capturing tumor heterogeneity in vitro, and genetically engineered mouse models for mechanistic insights. This diverse portfolio ensures robust, scalable studies that accurately reflect complex human tumor biology.
Rigorous Aseptic Procedures
We maintain strict aseptic verification procedures across all biological assays and model systems. This meticulous attention to detail minimizes contamination risks, guaranteeing the purity of cell cultures and the integrity of in vivo models, which is crucial for generating reliable and interpretable experimental results.
Workflow of PARPi-Based Combination Therapy Development
Highlights
Unrivaled Scientific Expertise
Our deep expertise translates into profound insights and efficient problem-solving for the most complex challenges in DNA repair biology and cancer therapeutics, guiding your project with precision.
State-of-the-Art Platforms & Infrastructure
We leverage advanced facilities equipped with cutting-edge high-throughput screening technologies, sophisticated in vitro and in vivo modeling systems, and comprehensive analytical instrumentation.
Integrated and Efficient Approach
Our holistic and integrated approach ensures seamless progression through every development phase, from initial target validation to preclinical proof-of-concept, providing a highly effective route for your drug candidates.
Proven Track Record & Tangible Benefits
Our clients consistently experience measurable improvements. On average, they achieve a 30% increase in drug lead compound screening efficiency and a 25% reduction in preclinical development costs.
Experience the Creative Biolabs advantage - Get a quote today.
Customer Reviews
-
Precision Biomarker Discovery
Creative Biolabs' expertise in comprehensive HRD scoring, integrating metrics like loss of heterozygosity (LOH), large-scale state transitions (LST), and telomeric allele imbalance (TAI), along with functional assays such as RAD51 foci formation, provided the clarity we needed. - Dr. A. Joh***on
-
Overcoming Resistance Challenges
We faced significant hurdles with acquired resistance to our PARPi candidate, which threatened to derail our development efforts. Creative Biolabs' comprehensive analysis of resistance mechanisms provided actionable insights. These detailed reports were instrumental in allowing us to design effective combination strategies and re-sensitize tumors, ultimately putting our program back on track. - Dr. M. Wan***g
FAQs
How does Creative Biolabs' service help identify new targets beyond BRCA mutations for PARP inhibitors?
Our advanced genomic profiling systematically uncovers novel DDR deficiencies and synthetic lethal partners. This includes identifying "BRCAness" phenotypes and other genetic vulnerabilities like ATM, ATR, and CDK12 deficiencies, significantly expanding therapeutic opportunities beyond traditional BRCA mutations.
Can Creative Biolabs assist with developing combination therapies involving PARP inhibitors, particularly with immunotherapies?
We specialize in investigating synergistic effects of PARP inhibitors with various agents, including traditional chemotherapy, radiation, and notably, cutting-edge immunotherapies. Our expertise extends to understanding the intricate preclinical rationale for PARPi-immunotherapy combinations.
Related Services
Creative Biolabs offers a suite of complementary services designed to support your entire oncology drug development journey.
Toxicology & Safety Assessment
Our detailed evaluation of drug safety profiles supports regulatory submissions. We conduct various toxicity studies, including acute and repeat-dose studies, genotoxicity, and safety pharmacology, to identify potential adverse effects.
Learn More →
Biomarker Discovery
Dedicated services include discovering predictive biomarkers to identify patient populations most likely to respond to a therapy, as well as prognostic and pharmacodynamic biomarkers to monitor treatment efficacy.
Learn More →
How to Contact Us
At Creative Biolabs, we are dedicated to accelerating your journey toward breakthrough oncology therapies. Our PARP inhibitor-based DNA damage response-targeting therapeutic development service is designed to provide the scientific rigor, advanced technology, and expert guidance you need to succeed. Partner with us to navigate the complexities of drug discovery faster. Contact us for more information and to discuss your project.
Reference
-
Livraghi, Luca, and Judy E. Garber. "PARP inhibitors in the management of breast cancer: current data and future prospects." BMC medicine 13.1 (2015): 188. Distributed under an Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.1186/s12916-015-0425-1
For Research Use Only | Not For Clinical Use
